Anti-rubella, Mumps and Measles IgG Antibodies in Medical Students of Tehran University
-
Maryam Keshavarz
,
Mohammad Hossein Nicknam
,
Majid Tebyanian
,
Mohammad Kazem Shahkarami
,
Maryam Izad
Abstract
Measles, mumps and rubella are viral infectious diseases that may result in serious complications. Since the production of vaccines, the number of cases of these diseases has been dropped. Nevertheless, these infectious diseases are still one of the major health problems in developing countries. In this study, in order to evaluate the protective responses against measles, mumps and rubella, the level and avidity of virus-specific IgG antibodies were measured in 53 medical students of Tehran University, aged between 20-30 years. Except for mumps vaccine, all the students had been vaccinated against measles and rubella according to Iran’s nationwide mass vaccination protocol for all persons aged 5–25 in 2003. Our results showed that 96.2% of the volunteers had a protective level (>15 IU/ml) of IgG against rubella, 79.2% had a protective level (>11 IU/ml) of IgG against measles and 64.16% had a protective level (>11 IU/ml) of IgG against mumps. Over ten years after nationwide measles-rubella vaccination campaign, most young adults aged 20-30 had protective levels of humoral immunity against measles and rubella. However, Iranian young population is still unvaccinated against mumps, and therefore relatively large number of young adults had no protective level of IgG against it. This finding may be due to reduction in circulating of wild strain. We recommend screening of medical students for immunity against infectious agents such as measles, mumps, rubella, because they are at a high risk of these infectious agents.
1. Hickman C, Mercader S, McGrew M, Williams N, Beeler JA, Audet S, et al. Laboratory characterization of measles virusinfection in previously vaccinated and unvaccinated individuals. J Infect Dis 2011; (204 Suppl 1):5549-8.
2. Haralambieva IH, Simon WL, Kennedy RB, Ovsyannikova IG, Warner ND, Grill DE, et al. Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays. Viruses 2015; 7(3):1113-33.
3. LeBaron CW, Forghani B, Beck C, Brown C, Bi D, Cossen C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 199(4):552–60.
4. Kennedy RB, Ovsyannikova IG, Haralambieva IH, Lambert ND, Pankratz VS, Poland GA. Genetic polymorphisms associated with rubella virus-specific cellular immunity following MMR vaccination. Hum Genet 2014; 133(11):1407–17.
5. Bautista-Lopez N, Ward B, Mills E, McCormick D, Martel N, Ratnam S. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 2000; 18(14):1393-401.
6. Robertson SE, Featherstone DA, Gacic-Dobo M, Hersh BS. Rubella and congenital rubella syndrome:global update. Rev Panam Salud Publica 2003; 14(5):306–15.
7. Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K et al. Measles outbreak California, December 2014– February 2015. MMWR Morb Mortal Wkly Rep 2015 64(6):153-4.
8. Rubin S, Dayan G. Mumps Outbreaks in Vaccinated Populations: Are AvailableMumps Vaccines Effective Enough to Prevent Outbreaks? Clin Infect Dis 2008;47(11):1458-67.
9. Ujiie M, Nabae K, Shobayashi T. Rubella outbreak inJapan. Lancet 2014; 383(9927):1460–1.
10. Centers for Disease Control and Prevention. Nationwide rubella epidemic-Japan, 2013. MMWR Morb Mortal Wkly Rep 2013; 62(23):457-62.
11. Corbin V , Beytout J , Auclair C, Chambon M, Mouly D, Chamoux A, et al. Shift of the 2009-2011 measles outbreak from children to adults: an observational review at the University Hospital of Clermont-Ferrand, France. Infection 2013; 41(6):1157-61.
12. Zahraei SM, Gouya MM, Azad TM, Soltanshahi R, Sabouri A, Naouri B, et al. Successful control and impending eliminationof measles in the Islamic Republic of Iran. J Infect Dis 2011; (204 Suppl 1):5305-11.
13. Esteghamati A, Zahraei SM, Dadras MN, Rashidi A, Mahoney F. Progress in Measles and Rubella Elimination in Iran. Pediatr Infect Dis J 2007; 26(12):1137-41.
14. Avijgan M, Hafizi M, Moghni M, Kheiri S, Esteghamati A, Sarikhani S. Immunogenicity and efficacy of the Hoshino strain of mumps (MMR Vaccine) in Iran. East Afr J Public Health 2011; 8(2):88-91.
15. Date AA, Kyaw MH, Rue AM, Klahn J, Obrecht L, Krohn T, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis2008; 197(12):1662-8.
16. Tosh PK, Kennedy RB, Vierkant RA, Jacobson RM, Poland GA. Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity. Viral Immunol 2009; 22(6):451-6.
17. Paunio M, Hedman K, Davidkin I, Valle M, Heinonen OP, Leinikki P, et al. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect 2000; 124(2):263-71.
18. Hamkar R, Mahmoodi M, Nategh R, Jelyani KN, Eslami MB, Mohktari-Azad T. Distinguishing between primary measles infection and vaccinefailure reinfection by IgG avidity assay. East Mediterr Health J 2006; 12(6):775-82.
19. Abbas K, Litchman A,Pillai Sh, Cellular and molecular immunology, ed. E. edition. 2012, Canada: Saunders, an imprint of Elsevier Inc.
20. Hamkar R, Jalilvand S, Abdolbaghi MH, Jelyani KN, Esteghamati A, Hagh-goo A, et al. Distinguishing between primaryinfection and reinfection with rubella vaccine virus by IgG avidity assay in pregnant women. East Medi Health J 2009; 15(1):94-103.
21. Yoshida N1, Fujino M, Miyata A, Nagai T, Kamada M,Sakiyama H, et al. Mumps virus reinfection is not a rare event confirmed by reverse transcription loop-mediated isothermal amplification. J Med Virol 2008; 80(3):517-23.
22. Mubareka S, Richards H, Gray M, Tipples GA.Evaluation of Commercial Rubella Immunoglobulin G Avidity Assays. J Clin Microbiol 2007; 45(1):231-3.
23. Honarvar B, Moghadami M, Moattari A, Emami A, Odoomi N, Bagheri Lankarani K. Seroprevalence of Anti- Rubella and Anti-Measles IgG Antibodies in Pregnant Women in Shiraz, Southern Iran: Outcomes of a Nationwide Measles-Rubella Mass Vaccination Campaign. PLoS One 2013; 8(1):e55043.
24. Shakurnia A, Alavi M, Norouzirad R. Post-Vaccination Immunity Against Measles in Under Twenty-Five-Year- Old Population of Ahvaz, Southwest of Iran. Jundishapur J Microbiol 2013; 6(10):e7707.
25. Hussain H, Akram DS, Chandir S, Khan AJ, Memon A, Halsey NA. Immune response to 1 and 2 dose regimens of Measles vaccine in Pakistani children. Hum Vaccin Immunother 2013; 9(12):2529-32.
26. Avijgan M, Habibian R, Kheiri S. Seroprevalence of mumps before inclusion of mumps vaccination in the Iranian Expanded Programme on Immunization. East Mediterr Health J 2009; 15(2):295-301.
27. Sanz-Moreno JC, Limia-Sánchez A, García-Comas L, Mosquera-Gutiérrez MM, Echevarria-Mayo JE, Castellanos-Nadal A, et al. Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G. Vaccine 2005; 23(41):4921-5.
28. Namaei MH, Ziaee M, Naseh N. Congenital rubella syndrome in infants of women vaccinated during or just before pregnancy with measles-rubella vaccine. Indian J Med Re, 2008; 127(6):551-4.
29. Sadighi J, Eftekhar H, Mohammad K. Congenital rubella
syndrome in Iran. BMC Infect Dis 2005; 5(44).
30. Mansour-Ghanaei F, Rahimi H, Joukar F, Bagherzaheh AH, Heidarzadeh A, Rahbar A, et al. Mass vaccination of measles and rubella (MR) in Guilan, Northern Iran: Evaluation of coverage and complications. Iran Red Cres Med J 2008; 10(3):173-9.
31. Tavana M, Gooya M, Iraqizadeh H. Mass vaccination in Iranian populations against rubrlla and measles. Inter J viro 2007; 3(1):12-8.
32. Rubin S, Mauldin J, Chumakov K, Vanderzanden J, Iskow R, Carbone K. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. Vaccine 2006; 24(14):2662-8.
33. Roustai MH, Nategh R, Noroozi M, Eslami MB, Mahmoodi M, Mokhtariazad T, et al. Determination of neutralizing antibodies against the mumps virus in selected groups in Tehran and two Iranian villages. Med J Islam Rep Iran 1996; 10(3):197-201.
34. Noorbakhsh S JN, Tonekaboni H,Tabatabaei A, Fatoorechi MA. Specific Anti Mumps Antibodies (IgG
& IgM) in Cerebrospinal Fluid of Mumps
Meningoencephalitic Children. Acta Medica Iranica
2009; 74(3):171-4.
35. Noorbakhsh S, Rimaz S,Tabatabaei A, Bakhshayesh M.Mumps meningoencephalitis in pediatric ward ofrasool akram hospital in tehran, iran, 1999-2000. Med J Islam Rep Iran 2004;18(2):123-6.
36. Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007; 45(4):459-66.
37. Betáková T, Svetlíková D, Gocník M. Overview of measles and mumps vaccine: origin, present, and future of vaccine production. Acta Virol 2013; 57(2):91-6.
38. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. Jama 2000; 284(20):2643-7.
39. Avijgan M, Hafizi M, Moghni M, Kheiri S, Esteghamati A, Sarikhani S. Immunogenicity and efficacy of the Hoshino strain of mumps Vaccine in Iran. East Afr J Public Health 2011; 8(2):88-91.
| Files | ||
| Issue | Vol 15, No 3 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Measles Mumps Rubella | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
